This practical guide for advanced students and decision-makers in the pharma and biotech industry presents key success factors in R&D along with value creators in pharmaceutical innovation. A team of editors and authors with extensive experience in academia and industry and at some of the most prestigious business schools in Europe discusses in detail the innovation process in pharma as well as common and new research and innovation strategies. In doing so, they cover collaboration and partnerships, open innovation, biopharmaceuticals, translational medicine, good manufacturing practice, regulatory affairs, and portfolio management. Each chapter covers controversial aspects of recent developments in the pharmaceutical industry, with the aim of stimulating productive debates on the most effective and efficient innovation processes. A must-have for young professionals and MBA students preparing to enter R&D in pharma or biotech as well as for students on a combined BA/biomedical and natural sciences program.
This open access book explores the field of life science business from a multidisciplinary perspective.
This is the first book to furnish a root cause of the low valuation of Japanese listed companies by using, as qualitative evidence, unique global investor surveys, which are rarely available for Japanese companies.
This book attempts to capture innovation outcomes.
The present book broadens this understanding of collaborative value creation in several respects: It employs a unique single-industry dataset at the European level.
Chi-Jen Lee reports a minimum of four months for approving an AIDS drug by the FDA in Lee, Chi-Jen (1993), Development and Evaluation of Drugs: From Laboratory through Licensure to Market, p. 68. See the empirical study from Kaitin, ...
An illustration of this is the failed acquisition of AstraZeneca by US pharmaceutical giant Pfizer in spring 2014, when the British, despite strong strategic synergies, decided to reject an $117bn takeover bid, due to an insufficient price ...
The book addresses in detail key issues of strategy and industry structure, describes best practice in the core functions of the chemical business system, looks at the state of the art in organization and post-merger management, and covers ...
The impact of market inefficiency on TOB in Japan / Tatsushi Yamamoto -- 7. A survey of public-to-private buy-out transactions in Japan / Keiichi Sugiura -- 8. Do M&As in Japan increase shareholder value? / Kotaro Inoue.
Mergers and Productivity offers probing analyses of high-profile mergers in a variety of industries. Focusing on specific acquisitions, it illustrates the remarkable range of contingencies involved in any merger attempt.
This book examines the business models, performance, and decision-making approaches employed by financial institutions in Central and Southeast Europe.